Format

Send to

Choose Destination
Sci Rep. 2016 Sep 1;6:32487. doi: 10.1038/srep32487.

Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo.

Author information

1
Dipartimento di Biologia e Biotecnologie, Università degli Studi di Pavia, Via Ferrata, 1-27100 Pavia, Italy.
2
Lab for Biomedicinal Chemistry, Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow 119071, Russia.
3
Lab of Pharmaceutical Microbiology, Ghent University, Ottergemsesteenweg 460, Ghent, 9000, Belgium.
4
Department of Microbiology, Baku State University, Z. Khalilov 23, AZ1148, Baku, Azerbaijan.
5
Neurosurgery, Dipartimento di Scienze Clinico-Chirurgiche e Pediatriche, Università degli Studi di Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
6
IGM-CNR, Via Abbiategrasso 207, 27100, Pavia, Italy.

Abstract

Burkholderia cenocepacia, an opportunistic respiratory pathogen particularly relevant for cystic fibrosis patients, is difficult to eradicate due to its high level of resistance to most clinically relevant antimicrobials. Consequently, the discovery of new antimicrobials as well as molecules capable of inhibiting its virulence is mandatory. In this regard quorum sensing (QS) represents a good target for anti-virulence therapies, as it has been linked to biofilm formation and is important for the production of several virulence factors, including proteases and siderophores. Here, we report the discovery of new diketopiperazine inhibitors of the B. cenocepacia acyl homoserine lactone synthase CepI, and report their anti-virulence properties. Out of ten different compounds assayed against recombinant CepI, four were effective inhibitors, with IC50 values in the micromolar range. The best compounds interfered with protease and siderophore production, as well as with biofilm formation, and showed good in vivo activity in a Caenorhabditis elegans infection model. These molecules were also tested in human cells and showed very low toxicity. Therefore, they could be considered for in vivo combined treatments with established or novel antimicrobials, to improve the current therapeutic strategies against B. cenocepacia.

PMID:
27580679
PMCID:
PMC5007513
DOI:
10.1038/srep32487
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center